avtar 75 nt vanddispergerbart granulat
indofil industries limited (netherlands) - mancozeb - vanddispergerbart granulat - 750 g/kg mancozeb
manfil 80 wp vanddispergerbart pulver
indofil industries limited (italy) - mancozeb - vanddispergerbart pulver - 800 g/kg mancozeb
velcade
janssen-cilag international nv - bortezomib - multipelt myelom - antineoplastiske midler - velcade som monoterapi eller i kombination med pegyleret liposomal doxorubicin eller dexamethason er indiceret til behandling af voksne patienter med gradvise myelomatose, der har modtaget mindst 1 forudgående terapi og der har allerede gennemgået eller er uegnet til hæmatopoietisk stamcelletransplantation. velcade i kombination med melphalan og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, der ikke er berettiget til høj-dosis kemoterapi med hæmatopoietisk stamcelle transplantation. velcade i kombination med dexamethason, eller med dexamethason og thalidomid, der er angivet for induktion behandling af voksne patienter med tidligere ubehandlet myelomatose, der er berettiget til høj-dosis kemoterapi med hæmatopoietisk stamcelle transplantation. velcade i kombination med rituximab, cyclophosphamid, doxorubicin og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet mantle celle lymfom, der er uegnede til hæmatopoietisk stamcelle transplantation.
myocet liposomal (previously myocet)
teva b.v. - doxorubicinhydrochlorid - bryst neoplasmer - antineoplastiske midler - myocet liposomal, i kombination med cyclophosphamid, er angivet for den første linje behandling af metastatisk brystkræft hos voksne kvinder.
tulissin
virbac s.a. - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.
increxxa
elanco gmbh - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.
desloratadine ratiopharm
ratiopharm gmbh - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk brug, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.
livogiva
theramex ireland limited - teriparatid - osteoporose - calciumhomeostase - livogiva is indicated in adults. behandling af osteoporose hos postmenopausale kvinder og hos mænd med øget risiko for brud. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling af osteoporose, der er forbundet med vedvarende systemisk glukokortikoid behandling, kvinder og mænd med øget risiko for fraktur.
blincyto
amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
sondelbay
accord healthcare s.l.u. - teriparatid - osteoporose - calciumhomeostase - sondelbay is indicated in adults. behandling af osteoporose hos postmenopausale kvinder og hos mænd med øget risiko for brud. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling af osteoporose, der er forbundet med vedvarende systemisk glukokortikoid behandling, kvinder og mænd med øget risiko for fraktur.